Gland Pharma Q2 Results FY27: PAT Jumps 58.3% to Rs 290.76 Cr, Revenue Rs 1,833.59 Cr
- November 6, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Gland Pharma Q2 Results FY27 were declared on 6 November 2026 for the July to September 2026 quarter. Consolidated revenue stood at Rs 1,833.59 Cr, up 23.32% YoY from Rs 1,486.88 Cr, while net profit came in at Rs 290.76 Cr, up 58.3% YoY from Rs 183.68 Cr. These quarterly results, reported as consolidated results, show YoY growth on both lines.
Gland Pharma Ltd (GLAND) Q2 Results FY27 announced on 6 November 2026, covering the company’s financial performance for the July to September 2026 quarter. The consolidated results show revenue of Rs 1,833.59 Cr and PAT of Rs 290.76 Cr, and Gland Pharma Q2 Results FY27 set the results date that anchors every figure in this article.
This results analysis of Gland Pharma Q2 Results tracks the reported numbers on NSE and BSE through financial highlights, business drivers, outlook and risks, and it begins with the table of reported figures below.
Click Here – Get Free Investment Predictions
Gland Pharma Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 1833.59 Cr | Rs 1486.88 Cr | +23.32% YoY |
| Operating Profit | Rs 484.04 Cr | Rs 313.89 Cr | +54.21% YoY |
| Net Profit (PAT) | Rs 290.76 Cr | Rs 183.68 Cr | +58.3% YoY |
Source: company filing for Gland Pharma Q2 Results FY27, 6 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Gland Pharma Q2 Results: What Stands Out
- Revenue grew 23.32% YoY to Rs 1,833.59 Cr from Rs 1,486.88 Cr, an expansion in the consolidated top line.
- Operating Profit rose 54.21% YoY to Rs 484.04 Cr from Rs 313.89 Cr, a gain larger than the revenue growth rate.
- Net profit rose 58.3% YoY to Rs 290.76 Cr from Rs 183.68 Cr, so YoY growth was positive across all three lines in Gland Pharma Q2 Results FY27.
- Net profit margin improved to 15.9% from 12.4% in the comparison quarter, a rise that fits profit growing faster than sales.
- Net profit was down 8.3% quarter on quarter from Rs 316.96 Cr, and the performance analysis next places this against the YoY gains.
Gland Pharma Q2 Results FY27: Performance Analysis
Gland Pharma Q2 Results FY27 show consolidated revenue of Rs 1,833.59 Cr against Rs 1,486.88 Cr a year earlier, a rise of 23.32%, while Operating Profit moved from Rs 313.89 Cr to Rs 484.04 Cr, a rise of 54.21%. Net profit rose 58.3% from Rs 183.68 Cr to Rs 290.76 Cr. The quarterly results therefore show profit lines rising faster than sales.
The arithmetic is plain: revenue added Rs 346.71 Cr, Operating Profit added Rs 170.15 Cr and net profit added Rs 107.08 Cr. Net profit margin improved to 15.9% from 12.4% in the comparison quarter. This results analysis of Gland Pharma Q2 Results FY27 rests only on the reported consolidated results, and the data confirms the numbers but does not establish the specific cause.
Investors following Gland Pharma Q2 Results can use the Univest Screener to watch the next quarterly filings and see whether YoY growth in profit keeps its lead over revenue. That is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points to revenue growth as the first factor: revenue grew 23.3% year on year to Rs 1,833.59 Cr in the latest quarter, which gives Gland Pharma Q2 Results FY27 a larger sales base than a year earlier.
Net Profit Margin – Net profit margin improved to 15.9% from 12.4% in the comparison quarter, which is why net profit rose 58.3% year on year while revenue rose 23.3% over the same period.
Four Quarters of Higher Revenue – Revenue has risen in each of the last 4 quarters, and the quarterly results therefore extend a run of consecutive sequential gains in the top line, as recorded in the reported series.
FY27 Outlook After Gland Pharma Q2 Results
FY27 full-year results for Gland Pharma will depend on how revenue and net profit move over the coming quarters. This results analysis treats the current quarter as one reference point, with revenue at Rs 1,833.59 Cr and net profit at Rs 290.76 Cr, and Gland Pharma Q2 Results FY27 give the base for comparison.
Three figures set the tone for the next update: the 23.32% revenue growth, the 54.21% rise in Operating Profit and the 15.9% net profit margin. Readers can compare each upcoming disclosure through the Univest app against these numbers. The next section lists the risks that the reported figures highlight.
Key Risks to Watch After Gland Pharma Q2 Results FY27
Quarter on Quarter Profit Dip
Net profit was down 8.3% quarter on quarter from Rs 316.96 Cr. This sequential move is the first item to monitor beside the Gland Pharma Q2 Results FY27 data, because it sits against the YoY growth in profit.
Return on Equity Below 15%
Return on equity of 10.56% in FY26 is below 15%. This annual ratio gives context to the quarterly results and shows the level of return on shareholder funds that investors may track.
Sequential Profit Gap
Net profit of Rs 290.76 Cr compares with Rs 316.96 Cr in the previous quarter, a gap of Rs 26.20 Cr. That gap is the figure to watch in later quarterly results for a sign of the sequential direction.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Gland Pharma Q2 Results FY27 show consolidated revenue up 23.32% YoY to Rs 1,833.59 Cr and net profit up 58.3% YoY to Rs 290.76 Cr. Together these quarterly results describe growth on every reported line alongside a sequential profit dip. The consolidated results in Gland Pharma Q2 Results also show Operating Profit at Rs 484.04 Cr. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Gland Pharma Q2 Results FY27
What are Gland Pharma Q2 Results FY27?
Ans. Gland Pharma Q2 Results FY27 cover the July to September 2026 quarter, with consolidated revenue of Rs 1,833.59 Cr and net profit of Rs 290.76 Cr, as the Financial Highlights table shows.
What is the results date for Gland Pharma Q2 Results FY27?
Ans. The results date for Gland Pharma Q2 Results FY27 is 6 November 2026, alongside which the opening paragraphs of this article set out revenue of Rs 1,833.59 Cr and net profit of Rs 290.76 Cr.
What revenue was reported in Gland Pharma Q2 Results FY27?
Ans. Gland Pharma reported revenue of Rs 1,833.59 Cr for Q2 FY27, compared with Rs 1,486.88 Cr a year earlier, which means revenue grew 23.32% as the Performance Analysis section explains.
What net profit was reported in Gland Pharma Q2 Results FY27?
Ans. Gland Pharma reported net profit of Rs 290.76 Cr for Q2 FY27, compared with Rs 183.68 Cr a year earlier, so net profit rose 58.3% as the Financial Highlights table shows.
How much YoY growth did revenue show in Gland Pharma Q2 Results FY27?
Ans. Revenue showed YoY growth of 23.32% in Gland Pharma Q2 Results FY27, rising from Rs 1,486.88 Cr to Rs 1,833.59 Cr, which means the top line expanded, as the Performance Analysis explains.
Did net profit rise or fall in Gland Pharma Q2 Results?
Ans. Net profit rose in Gland Pharma Q2 Results, moving from Rs 183.68 Cr to Rs 290.76 Cr, a 58.3% increase, while revenue rose 23.32%, as the Key Takeaways section notes.
What was the Operating Profit in Gland Pharma Q2 Results FY27?
Ans. Operating Profit was Rs 484.04 Cr in Gland Pharma Q2 Results FY27, up 54.21% from Rs 313.89 Cr a year earlier, which means it rose faster than revenue, as the Financial Highlights table shows.
Are Gland Pharma Q2 Results consolidated results or standalone results?
Ans. Gland Pharma Q2 Results are consolidated results, with revenue of Rs 1,833.59 Cr and net profit of Rs 290.76 Cr reported on a consolidated basis, as the Quick Answer shows.
What business factors shaped Gland Pharma Q2 Results FY27?
Ans. Revenue growth of 23.3%, a net profit margin of 15.9% against 12.4% and four straight quarters of higher revenue are the disclosed factors, covered in the Key Business Factors section.
What are the key risks after Gland Pharma Q2 Results FY27?
Ans. The key risks after Gland Pharma Q2 Results FY27 are the 8.3% sequential dip in net profit and a return on equity of 10.56% that sits below 15%, which are detailed in the Key Risks section.
What is the outlook after Gland Pharma Q2 Results?
Ans. FY27 full-year results will depend on how revenue and net profit move in coming quarters, so the Outlook section treats the current quarter as one reference point with revenue of Rs 1,833.59 Cr.
Where can I find the complete Gland Pharma Q2 Results FY27 data?
Ans. The complete Gland Pharma Q2 Results FY27 data is in the company’s filing of 6 November 2026 on NSE and BSE, while the Univest app and Screener help track later quarterly results.
